Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy

British Journal of Pharmacology

Volumn 174, Issue 24, 2017, Pages 4589-4599

  Lyou, Yung ^a   Habowski, Amber N ^b   Chen, George T ^b   Waterman, Marian L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BEVACIZUMAB; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MESSENGER RNA; MONOCARBOXYLATE TRANSPORTER 1; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE 1; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; WNT3A PROTEIN; ANTINEOPLASTIC AGENT;

AEROBIC GLYCOLYSIS; ANGIOGENESIS; AXIN2 GENE; BINDING AFFINITY; CANCER CELL; CANCER THERAPY; CCND1 GENE; CELL MEMBRANE; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; DRUG APPROVAL; ENZYME ACTIVITY; GENE EXPRESSION; GENE TARGETING; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; IC50; LEF1 GENE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE C MYC; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; TRANSCRIPTION REGULATION; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL NUCLEUS; DRUG EFFECT; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL NUCLEUS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 85038030197     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13963     Document Type: Review

References (91)

1. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A et al. (2012). OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30: 2039–2045.
2. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol 172: 5729–5743.
3. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol 172: 5979–6023.
4. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
5. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015d). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110–6202.
6. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M et al. (2009). Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457: 608–611.
7. Bodmer WF, Bailey CJ, Bodmer J, Bussey HJ, Ellis A, Gorman P et al. (1987). Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328: 614–616.
8. Brantjes H, Roose J, van De Wetering M, Clevers H (2001). All TCF HMG box transcription factors interact with Groucho-related co- repressors. Nucleic Acids Res 29: 1410–1419.
9. Cadigan KM, Waterman ML (2012). TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb Symp Quant Biol 4: 1–22.
10. Cancer Genome Atlas Network, Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA et al. (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330–337.
11. Chodaparambil JV, Pate KT, Hepler MRD, Tsai BP, Muthurajan UM, Luger K et al. (2014). Molecular functions of the TLE tetramerization domain in Wnt target gene repression. EMBO J 33: 719–731.
12. Choi H-J, Huber AH, Weis WI (2006). Thermodynamics of beta-catenin-ligand interactions: the roles of the N- and C-terminal tails in modulating binding affinity. J Biol Chem 281: 1027–1038.
13. Daniels DL, Eklof Spink K, Weis WI (2001). beta-catenin: molecular plasticity and drug design. Trends Biochem Sci 26: 672–678.
14. DeBruine Z, Xu E, Melcher K (2017). Assembly and architecture of the Wnt/β-catenin signalosome. Br J Pharmacol.
15. de la Roche M, Rutherford TJ, Gupta D, Veprintsev DB, Saxty B, Freund SM et al. (2012). An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid. Nat Commun 3: 680.
16. Driehuis E, Clevers H (2017). WNT signalling events near the cell membrane and their pharmacological targeting for the treatment of cancer. Br J Pharmacol 1–17.
17. Duchartre Y, Kim Y-M, Kahn M (2016). The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol 99: 141–149.
18. El-Khoueiry AB, Ning Y, Yang N, Cole S, Kahn M, Zoghbi M et al. (2013). A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol 31 no pagination.
19. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M et al. (2004). A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A 101: 12682–12687.
20. Ewan K, Pajak B, Stubbs M, Todd H, Barbeau O, Quevedo C et al. (2010). A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res 70: 5963–5973.
21. Fang L, Zhu Q, Neuenschwander M, Specker E, Wulf-Goldenberg A, Weis WI et al. (2016). A small-molecule antagonist of the β-catenin/TCF4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis. Cancer Res 76: 891–901.
22. Fasolini M, Wu X, Flocco M, Trosset JY, Oppermann U, Knapp S (2003). Hot spots in Tcf4 for the interaction with ??-catenin. J Biol Chem 278: 21092–21098.
23. Fiedler M, Graeb M, Mieszczanek J, Rutherford TJ, Johnson CM, Bienz M (2015). An ancient Pygo-dependent Wnt enhanceosome integrated by Chip/LDB-SSDP. Elife 4: https://doi.org/10.7554/eLife.09073.
24. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO et al. (2015). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16: 25–35.
25. Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K et al. (2016). Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375: 1925–1936.
26. Garber K (2016). Cancer anabolic metabolism inhibitors move into clinic. Nat Biotechnol 34: 794–795.
27. Goel S, Wong AH, Jain RK (2012). Vascular normalization as a therapeutic strategy. Cold Spring Harb Perspect Med 2: 1–24.
28. Gonsalves FC, Klein K, Carson BB, Katz S, Ekas LA, Evans S (2011). An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci U S A 108: 5954–5963.
29. Gore AV, Swift MR, Cha YR, Lo B, McKinney MC, Li W et al. (2011). Rspo1/Wnt signaling promotes angiogenesis via Vegfc/Vegfr3. Development 138: 4875–4886.
30. Graham TA, Weaver C, Mao F, Kimelman D, Xu W (2000). Crystal structure of a beta-catenin/Tcf complex. Cell 103: 885–896.
31. Guthrie ML, Sidhu PS, Hill EK, Horan TC, Nandhikonda P, Teske KA et al. (2015). Antitumor activity of 3-indolylmethanamines 31B and PS121912. Anticancer Res 35: 6001–6007.
32. He X, Zhang W, Yan C, Nie F, Li C, Liu X et al. (2017). Chemical biology reveals CARF as a positive regulator of canonical Wnt signaling by promoting TCF/β-catenin transcriptional activity. Cell Discov 3: 17003.
33. Hecht A, Vleminckx K, Stemmler MP, van Roy F, Kemler R (2000). The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J 19: 1839–1850.
34. Hoggard LR, Zhang Y, Zhang M, Panic V, Wisniewski JA, Ji H (2015). Rational design of selective small-molecule inhibitors for β-catenin/B-cell lymphoma 9 protein-protein interactions. J Am Chem Soc 137: 12249–12260.
35. Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S et al. (2016). Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375: 1738–1748.
36. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342.
37. Hwang S-Y, Deng X, Byun S, Lee C, Lee S-J, Suh H et al. (2016). Direct targeting of β-catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/β-catenin signaling. Cell Rep 16: 28–36.
38. Jain RK (2014). Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26: 605–622.
39. Jin G, Lu D, Yao S, Wu CC, Liu JX, Carson DA et al. (2009). Amide derivatives of ethacrynic acid: synthesis and evaluation as antagonists of Wnt/beta-catenin signaling and CLL cell survival. Bioorg Med Chem Lett 19: 606–609.
40. Kahn M (2014). Can we safely target the WNT pathway? Nat Rev Drug Discov 13: 513–532.
41. van Kappel EC, Maurice MM (2017). Molecular regulation and pharmacological targeting of the β-catenin destruction complex. Br J Pharmacol.
42. Koh CM, Sabò A, Guccione E (2016). Targeting MYC in cancer therapy: RNA processing offers new opportunities. Bioessays 38: 266–275.
43. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW et al. (1997). Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science 275: 1784–1787.
44. Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S et al. (2002). Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell 109: 47–60.
45. Le PN, McDermott JD, Jimeno A (2015). Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther 146: 1–11.
46. Lee M, Chen GT, Edwards RA, Wang K, Waterman ML, Lowengrub J (2017). Mathematical modeling links Wnt signaling to emergent patterns of metabolism in colon cancer. Rev 13: 912.
47. Lee SY, Jeon HM, Ju MK, Kim CH, Yoon G, Han SI et al. (2012). Wnt/snail signaling regulates cytochrome c oxidase and glucose metabolism. Cancer Res 72: 3607–3617.
48. Lepourcelet M, Chen Y-NP, France DS, Wang H, Crews P, Petersen F et al. (2004). Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5: 91–102.
49. Levanon D, Goldstein RE, Bernstein Y, Tang H, Goldenberg D, Stifani S et al. (1998). Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc Natl Acad Sci U S A 95: 11590–11595.
50. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K et al. (2009). Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/β-catenin pathway. PLoS One 4: e8294.
51. Masckauchán TNH, Shawber CJ, Funahashi Y, Li C-M, Kitajewski J (2005). Wnt/β-catenin signaling induces proliferation, survival and interleukin-8 in human endothelial cells. Angiogenesis 8: 43–51.
52. Masuda T, Ishitani T (2017). JB special review – Wnt signaling: biological functions and its implications in diseases: context-dependent regulation of the β-catenin transcriptional complex supports diverse functions of Wnt/β-catenin signaling. J Biochem 161: 9–17.
53. Mazzoni SM, Fearon ER (2014). AXIN1 and AXIN2 variants in gastrointestinal cancers. Cancer Lett 355: 1–8.
54. McMahon AP, Moon RT (1989). Ectopic expression of the proto-oncogene int-1 in Xenopus embryos leads to duplication of the embryonic axis. Cell 58: 1075–1084.
55. McWilliams RR, Ko AH, Chiorean EG, Kwak EL, Lenz H-J, Nadler PI et al. (2015). A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. J Clin Oncol 33: (suppl); abstr e15270.
56. Mita MM, Becerra C, Richards DA, Mita AC, Shagisultanova E, Osborne CRC et al. (2016). Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC). J Clin Oncol 34: 2516.
57. Mohan M, Herz H-M, Takahashi Y-H, Lin C, Lai KC, Zhang Y et al. (2010). Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev 24: 574–589.
58. Mullard A (2016). Cancer metabolism pipeline breaks new ground. Nat Rev Drug Discov 15: 735–737.
59. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL (2011). Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11: 558–572.
60. Nguyen H, Merrill BJ, Polak L, Nikolova M, Rendl M, Shaver TM et al. (2009). Tcf3 and Tcf4 are essential for long-term homeostasis of skin epithelia. Nat Genet 41: 1068–1075.
61. Niehrs C, Acebron SP (2012). Mitotic and mitogenic Wnt signalling. EMBO J 31: 2705–2713.
62. Nusse R, Clevers H (2017). Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 169: 985–999.
63. Nusse R, Varmus HE (1982). Many Tumors Induced by the Mouse Mammary Tumor Virus Contain a Provirus Integrated in the Same Region of the Host Genome. Cell 31: 99–109.
64. Pate KT, Stringari C, Sprowl-Tanio S, Wang K, TeSlaa T, Hoverter NP et al. (2014). Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer. EMBO J 33: 1454–1473.
65. Polakis P (2012). Wnt signaling in cancer. Cold Spring Harb Perspect Biol 4 pii: a008052.
66. Poy F, Lepourcelet M, Shivdasani RA, Eck MJ (2001). Structure of a human Tcf4-beta-catenin complex. Nat Struct Biol 8: 1053–1057.
67. Rennoll S, Yochum G (2015). Regulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer. World J Biol Chem 6: 290–300.
68. Reya T, Clevers H (2005). Wnt signalling in stem cells and cancer. Nature 434: 843–850.
69. Rocheleau CE, Downs WD, Lin R, Wittmann C, Bei Y, Cha YH et al. (1997). Wnt signaling and an APC-related gene specify endoderm in early C. elegans embryos. Cell 90: 707–716.
70. Sampietro J, Dahlberg CL, Cho U, Hinds TR, Kimelman D, Xu W (2006). Crystal structure of a β-catenin/BCL9/Tcf4 complex. Mol Cell 24: 293–300.
71. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–2550.
72. Schmidt M, Sievers E, Endo T, Lu D, Carson D, Schmidt-Wolf IGH et al. (2009). Targeting Wnt pathway in lymphoma and myeloma cells. Br J Haematol 144: 796–798.
73. Sherwood V, Chaurasiya SK, Ekström EJ, Guilmain W, Liu Q, Koeck T et al. (2014). WNT5A-mediated ß-catenin-independent signalling is a novel regulator of cancer cell metabolism. Carcinogenesis 35: 784–794.
74. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al. (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: Towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44: D1054–D1068.
75. Sprowl-Tanio S, Habowski AN, Pate KT, McQuade MM, Wang K, Edwards RA et al. (2016). Lactate/pyruvate transporter MCT-1 is a direct Wnt target that confers sensitivity to 3-bromopyruvate in colon cancer. Cancer Metab 4: 20.
76. Sun Y, Kolligs FT, Hottiger MO, Mosavin R, Fearon ER, Nabel GJ (2000). Regulation of beta -catenin transformation by the p300 transcriptional coactivator. Proc Natl Acad Sci 97: 12613–12618.
77. Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao J-J, Mani M et al. (2012). Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med 4: 148ra117–148ra117.
78. Takemaru KI, Moon RT (2000). The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J Cell Biol 149: 249–254.
79. Thompson B, Townsley F, Rosin-Arbesfeld R, Musisi H, Bienz M (2002). A new nuclear component of the Wnt signalling pathway. Nat Cell Biol 4: 367–373.
80. Tian W, Han X, Yan M, Xu Y, Duggineni S, Lin N et al. (2012). Structure-based discovery of a novel inhibitor targeting the beta-catenin/Tcf4 interaction. Biochemistry 51: 724–731.
81. van Tienen LM, Mieszczanek J, Fiedler M, Rutherford TJ, Bienz M (2017). Constitutive scaffolding of multiple Wnt enhanceosome components by Legless/BCL9. Elife 6: 1–23.
82. Townsley FM, Thompson B, Bienz M (2004). Pygopus residues required for its binding to Legless are critical for transcription and development. J Biol Chem 279: 5177–5183.
83. Turner NC, Ro J, André F, Loi S, Verma S, Iwata H et al. (2015). Palbociclib in hormone-receptor–Positive advanced breast cancer. N Engl J Med 373: 209–219.
84. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA et al. (2007). Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722–4729.
85. Waltzer L, Bienz M (1998). Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling. Nature 395: 521–525.
86. Wang W, Liu H, Wang S, Hao X, Li L (2011). A diterpenoid derivative 15-oxospiramilactone inhibits Wnt/β-catenin signaling and colon cancer cell tumorigenesis. Cell Res 21: 730–740.
87. Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM et al. (1998). Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 91: 1873–1881.
88. Xu W, Kimelman D (2007). Mechanistic insights from structural studies of beta-catenin and its binding partners. J Cell Sci 120: 3337–3344.
89. Zhan T, Rindtorff N, Boutros M (2016). Wnt signaling in cancer. Oncogene 4 pii: a008052.
90. Zhang X, Gaspard JP, Chung DC (2001). Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 61: 6050–6054.
91. Zimmerli D, Hausmann G, Cantù C, Basler K (2017). Pharmacological interventions in the Wnt pathway: inhibition of Wnt secretion versus disrupting the protein-protein interfaces of nuclear factors. Br J Pharmacol 1–11.